Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | NPC1 | O15118 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
| ▸ | DUT | P33316 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12794868 | 0.94 | RAB9A (0.38) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL986150 | 0.88 | DUT (0.38) | SMN1; SMN2DUTALDH1A1LMNAMAPK1 | |
| SCHEMBL986157 | 0.83 | ADORA2A (0.45) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL987310 | 0.83 | NPC1 (0.44) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL12794869 | 0.82 | KMT2A (0.35) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL12794872 | 0.81 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL984958 | 0.81 | KDM4E (0.46) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL984956 | 0.80 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL986392 | 0.80 | NPC1 (0.43) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL27772450 | 0.78 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| EP-2049556-B1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8173609-B2 | Macrolides useful against inflammatory and allergic diseases | BASILEA PHARMACEUTICA AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2247294-A2 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | Basilea Pharmaceutica AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | BASILEA PHARMACEUTICA AG (CH) | 2010-05-13 | — | — | US | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| EP-2049556-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | Basilea Pharmaceutica AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017696-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | BASILEA PHARMACEUTICA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | HRH4, HRH2, IL4 | RAB9A 2536/4885NPC1 1155/4885SMN1; SMN2 2728/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | RAB9A 1999/4885NPC1 869/4885SMN1; SMN2 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.